Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections

Balmès, P; Clerc, G.; Dupont, B.; Labram, C; Parienté, R; Poirier, R

doi:10.1007/bf01968024

Cited by 44 publications

(15 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Amoxicillin/clavulanate has normally been administered as a regimen of 500/125 mg (amoxicillin/clavulanate) every 8 hours for adults. In this regimen, the combination is as effective for treatment of lower respiratory tract infections as other agents such as loracarbef [6,7], cefuroxime [8], and azithromycin [9,10].…”

Section: Discussionmentioning

confidence: 99%

Dosing of Amoxicillin/Clavulanate Given Every 12 Hours Is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection

Calver¹,

Walsh²,

Quinn³

et al. 1997

Clinical Infectious Diseases

View full text Add to dashboard Cite

In this double-blind study, 557 patients with lower respiratory tract infection were randomly assigned to receive amoxicillin/clavulanate orally either every 12 hours (875/125 mg) or every 8 hours (500/125 mg) for 7 -15 days. For the 455 patients evaluable for clinical efficacy at the end of therapy, clinical success was similar in the two groups: 93% and 94% in the 12-hour and 8-hour groups, respectively (P = .42). Bacteriologic success at the end of therapy was also comparable: 97% and 91% in the 12-hour and 8-hour groups, respectively (P = .86). The occurrence of adverse events related to treatment was similar for the two groups, but fewer patients in the 12-hour group reported moderate or severe diarrhea. Amoxicillin/clavulanate (875/125 mg) given every 12 hours is as effective and safe as every-8-hours administration of the combination (500/125 mg) for the treatment of lower respiratory tract infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Dosing of Amoxicillin/Clavulanate Given Every 12 Hours Is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection

Calver¹,

Walsh²,

Quinn³

et al. 1997

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Azithromycin has previously been shown to be effective in treating patients with lower respiratory tract infections. Balmes and colleagues observed a favourable clinical response in 44 of 48 (92 %) patients with bacterial cure in 88 % of those who received azithromycin (10). However, the vast majority of patients in that study had acute bronchitis rather than pneumonia.…”

Section: Gens (Haemophilus Influenzae Moraxella (Branhamella) Catarrmentioning

confidence: 94%

“…In addition, in animal models of infection, azithromycin has been shown to be effective against the respiratory pathogens, Haemophihts influenzae, Streptococcus pneumoniae and Legionella pneumophila (8,9). A recent study demonstrated that azithromycin was comparable to anaoxicillin/clavulanic acid in a multicentre trial in 110 patients with bronchitis or pneumonia caused by Haemophilus influenzae, Haemophilus parainfluenzae, Streptococcus pneumoniae and Staphylococcus aureus (10). Clinical cure occurred in 36 of 48 patients (75 %) on azithromycin and clinical improvement in 8 of 48 (17 %).…”

mentioning

confidence: 96%

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

Kinasewitz

Wood

1991

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

In this randomised, double-blind study carried out in 28 centres, azithromycin (500 mg single dose on day 1, followed by 250 mg once-daily on days 2-5) was compared with cefaclor (500 mg t.i.d. for 10 days) in the treatment of acute bacterial pneumonia. A total of 119 patients entered the study, and of these 71 were evaluable and included in the efficacy analysis. The overall satisfactory clinical response was 97.3% for azithromycin patients and 100% for cefaclor patients. The clinical cure rates of azithromycin and cefaclor were 46.9% and 41.0%, respectively; improvement was seen in an additional 46.9% of azithromycin-treated patients and in 59.0% of the cefaclor group. The bacteriological eradication rates were 80.4% and 92.6%, respectively. These rates of clinical and bacteriological efficacy, were not statistically different. Both antibiotics were well tolerated during the study; only two patients (one on each study drug) discontinued medication due to adverse events. The overall incidence of side effects was 18.9% (10 of 53 patients) for azithromycin- and 12.1% (eight of 66 patients) for cefaclor-treated patients. Gastrointestinal disturbances were the most commonly reported side effects (nine of 10 azithromycin-treated patients and six of eight cefaclor-treated patients). In addition, two cefaclor patients reported headache. All azithromycin side effects were mild or moderate in severity, but there were two severe occurrences in the cefaclor group (1 nausea, 1 vomiting) the later leading to discontinuation.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…The clinical and bacteriological results of selected trials are summarized in Table 4 [140][141][142][143][144][145][146][147][148][149][150]. Overall, clinical success rates ranging from 81-100 and 86-97% were observed with azithromycin and clarithromycin, respectively; bacteriological success ranged from 80-94 and 89-95% respectively.…”

Section: Advantagesmentioning

confidence: 99%

Update on the use of the macrolides for community-acquired respiratory tract infections

Blondeau¹

2006

Therapy

View full text Add to dashboard Cite

Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections

Cited by 44 publications

References 4 publications

Dosing of Amoxicillin/Clavulanate Given Every 12 Hours Is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection

Dosing of Amoxicillin/Clavulanate Given Every 12 Hours Is as Effective as Dosing Every 8 Hours for Treatment of Lower Respiratory Tract Infection

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

Update on the use of the macrolides for community-acquired respiratory tract infections

Contact Info

Product

Resources

About